Cargando…

Clinician Attitudes to Using Low-Dose Radiation Therapy to Treat COVID-19 Lung Disease

PURPOSE: Current treatments for coronavirus disease 2019 (COVID-19) lung disease have limited efficacy. Low-dose radiation therapy (LDRT) has received both interest and criticism as a potential treatment for this condition. In this qualitative study we explored clinicians’ perspectives to identify b...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanna, Catherine R., Robb, Kathryn A., Blyth, Kevin G., Jones, Robert J., Chalmers, Anthony J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier, Inc 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7726525/
https://www.ncbi.nlm.nih.gov/pubmed/33309910
http://dx.doi.org/10.1016/j.ijrobp.2020.12.003
_version_ 1783620902843318272
author Hanna, Catherine R.
Robb, Kathryn A.
Blyth, Kevin G.
Jones, Robert J.
Chalmers, Anthony J.
author_facet Hanna, Catherine R.
Robb, Kathryn A.
Blyth, Kevin G.
Jones, Robert J.
Chalmers, Anthony J.
author_sort Hanna, Catherine R.
collection PubMed
description PURPOSE: Current treatments for coronavirus disease 2019 (COVID-19) lung disease have limited efficacy. Low-dose radiation therapy (LDRT) has received both interest and criticism as a potential treatment for this condition. In this qualitative study we explored clinicians’ perspectives to identify barriers to testing LDRT in clinical trials and implementing it in clinical practice. METHODS AND MATERIALS: Semistructured interviews were undertaken with 6 clinicians from 3 medical disciplines. Interviews were recorded, transcribed verbatim, and analyzed thematically, using a framework approach. Common themes regarding barriers to using LDRT for COVID-19 lung disease were identified from the data. RESULTS: Three categories of barriers emerged: (1) the potential to do harm to the patient, including difficulty in predicting harm and lack of existing data to inform quantification of risks; (2) the feasibility of trialing this novel treatment strategy in the clinical setting, in particular trial design and recruitment, patient selection and buy-in from relevant clinician groups; and (3) the logistics of delivering the treatment, in particular risks of transmission to other patients and resources required for patient transfer. CONCLUSIONS: This study identified several barriers that may impede the evaluation and subsequent implementation of LDRT as a treatment for COVID-19 lung disease, from the perspectives of clinicians in 3 relevant specialties. By documenting and articulating these concerns, we hope to enhance discussion of why these barriers exist, and enable them to be addressed in a proactive manner to facilitate research into the potential benefits of radiation treatment for patients with COVID-19 lung disease going forward.
format Online
Article
Text
id pubmed-7726525
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier, Inc
record_format MEDLINE/PubMed
spelling pubmed-77265252020-12-10 Clinician Attitudes to Using Low-Dose Radiation Therapy to Treat COVID-19 Lung Disease Hanna, Catherine R. Robb, Kathryn A. Blyth, Kevin G. Jones, Robert J. Chalmers, Anthony J. Int J Radiat Oncol Biol Phys COVID-19 Scientific Communication PURPOSE: Current treatments for coronavirus disease 2019 (COVID-19) lung disease have limited efficacy. Low-dose radiation therapy (LDRT) has received both interest and criticism as a potential treatment for this condition. In this qualitative study we explored clinicians’ perspectives to identify barriers to testing LDRT in clinical trials and implementing it in clinical practice. METHODS AND MATERIALS: Semistructured interviews were undertaken with 6 clinicians from 3 medical disciplines. Interviews were recorded, transcribed verbatim, and analyzed thematically, using a framework approach. Common themes regarding barriers to using LDRT for COVID-19 lung disease were identified from the data. RESULTS: Three categories of barriers emerged: (1) the potential to do harm to the patient, including difficulty in predicting harm and lack of existing data to inform quantification of risks; (2) the feasibility of trialing this novel treatment strategy in the clinical setting, in particular trial design and recruitment, patient selection and buy-in from relevant clinician groups; and (3) the logistics of delivering the treatment, in particular risks of transmission to other patients and resources required for patient transfer. CONCLUSIONS: This study identified several barriers that may impede the evaluation and subsequent implementation of LDRT as a treatment for COVID-19 lung disease, from the perspectives of clinicians in 3 relevant specialties. By documenting and articulating these concerns, we hope to enhance discussion of why these barriers exist, and enable them to be addressed in a proactive manner to facilitate research into the potential benefits of radiation treatment for patients with COVID-19 lung disease going forward. Elsevier, Inc 2021-03-15 /pmc/articles/PMC7726525/ /pubmed/33309910 http://dx.doi.org/10.1016/j.ijrobp.2020.12.003 Text en © 2020 The Authors http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle COVID-19 Scientific Communication
Hanna, Catherine R.
Robb, Kathryn A.
Blyth, Kevin G.
Jones, Robert J.
Chalmers, Anthony J.
Clinician Attitudes to Using Low-Dose Radiation Therapy to Treat COVID-19 Lung Disease
title Clinician Attitudes to Using Low-Dose Radiation Therapy to Treat COVID-19 Lung Disease
title_full Clinician Attitudes to Using Low-Dose Radiation Therapy to Treat COVID-19 Lung Disease
title_fullStr Clinician Attitudes to Using Low-Dose Radiation Therapy to Treat COVID-19 Lung Disease
title_full_unstemmed Clinician Attitudes to Using Low-Dose Radiation Therapy to Treat COVID-19 Lung Disease
title_short Clinician Attitudes to Using Low-Dose Radiation Therapy to Treat COVID-19 Lung Disease
title_sort clinician attitudes to using low-dose radiation therapy to treat covid-19 lung disease
topic COVID-19 Scientific Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7726525/
https://www.ncbi.nlm.nih.gov/pubmed/33309910
http://dx.doi.org/10.1016/j.ijrobp.2020.12.003
work_keys_str_mv AT hannacatheriner clinicianattitudestousinglowdoseradiationtherapytotreatcovid19lungdisease
AT robbkathryna clinicianattitudestousinglowdoseradiationtherapytotreatcovid19lungdisease
AT blythkeving clinicianattitudestousinglowdoseradiationtherapytotreatcovid19lungdisease
AT jonesrobertj clinicianattitudestousinglowdoseradiationtherapytotreatcovid19lungdisease
AT chalmersanthonyj clinicianattitudestousinglowdoseradiationtherapytotreatcovid19lungdisease